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Abstract 
Vascular smooth muscle cells (VSMCs) derived from cardiovascular progenitor 
cell (CVPC) lineage populate the tunica media of the aortic root. Understanding 
differentiation of VSMCs from CVPC will further our understanding of the 
molecular mechanisms contributing to aortic root aneurysms, and thus, facilitate 
the development of novel therapeutic agents to prevent this devastating 
complication. It is established that the yes-associated protein (YAP) and Hippo 
pathway is important for VSMC proliferation and phenotype switch. To determine 
the role of YAP in differentiation of VSMCs from CVPCs, we utilized the in vitro 
monolayer lineage specific differentiation method by differentiating human 
embryonic stem cells into CVPCs, and then, into VSMCs. We found that 
expression of YAP decreased during differentiation of VSMC from CVPCs. 
Overexpression of YAP attenuated expression of VSMC contractile markers and 
impaired VSMC function. Knockdown of YAP increased expression of contractile 
proteins during CVPC-VSMCs differentiation. Importantly, expression of YAP 
decreased transcription of myocardin during this process. Overexpression of YAP 
in PAC1 SMC cell line inhibited luciferase activity of myocardin proximal promoter 
in a dose dependent and NKX2.5 dependent manner. YAP protein interacted with 
NKX2.5 protein and inhibited binding of NKX2.5 to the 5’-proximal promoter 
region of myocardin in CVPC-derived VSMCs. In conclusion, YAP negatively 
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regulates differentiation of VSMCs from CVPCs by decreasing transcription of 
myocardin in a NKX2.5-dependent manner.  
 
Key words: Yes-associated protein, stem cells, vascular smooth muscle cell, 
cardiovascular progenitor cell, differentiation 
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Introduction 
Aortic aneurysms are associated with aortic dissection and rupture, which are 
lethal. There is no medical treatment to prevent or reverse aortic aneurysm. Aortic 
aneurysms could develop from the loss of vascular smooth muscle cells (VSMCs) 
in the media layer of the aortic wall leading to progressive aortic dilation. Sixty 
percent of aortic aneurysms involve the aortic root [1]. Specifically, the subgroup 
of VSMCs located in the media layer of aortic root is differentiated from second 
heart field-derived cardiovascular progenitor cells (CVPCs), thereby playing a 
critical role in the pathological progression of aortic root aneurysms [2]. There is a 
need to further elucidate the mechanisms in CVPC-derived VSMC differentiation 
so that novel therapeutic strategies can be developed to prevent aortic root 
aneurysm.  
Yes-associated protein (YAP) is a key co-transcription factor involved in the 
Hippo signaling that includes upstream kinases (NF2, MST1/2, LATS1/2), major 
co-transcription factors (YAP/TAZ), and transcription factors TEAD1-4 [3]. Our 
group, as well as evidence from other groups, found that Yap was a central 
regulator of the VSMC phenotype switch and neointima formation after artery 
injury in adult rodent models [4, 5]. Neural crest-specific deletion of Yap and Taz 
[6, 7] caused deficiency of neural crest development and subsequent VSMC 
differentiation. Conditional deletion of Yap with a Sm22α-Cre in mice showed that 
knockout of Yap was sufficient to impede VSMC proliferation resulting in vessel 
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wall thinning and vascular morphological defects [8]. These studies suggest that 
YAP plays an important role in VSMC repair and vascular development. However, 
it is unknown how YAP regulates the process of VSMCs differentiation from 
cardiovascular progenitor cell lineage.  
The development of human embryonic and induced pluripotent stem cells [9, 
10] has provided new sources to sizably derive VSMCs and offers valuable 
advantages for identifying novel factors in controlling VSMCs-lineage 
differentiation. As a newly developed humanized in vitro tool, in vitro monolayer 
VSMC differentiation demonstrated advantages in differentiation lineage, origin, 
and stage controlling [11, 12]. Importantly, differentiated VSMCs exhibited 
transcription and metabolomics profile similar to primary VSMCs [13]. Therefore, 
in vitro lineage and stage controlled human VSMC differentiation models can 
facilitate ways to dissect the modulators and pathways involved in different 
lineages and stages. It also can be utilized to improve quality of tissue engineered 
vascular grafts for future patient treatment. [14, 15]  
In this study, we adopted the in vitro monolayer VSMC differentiation system 
by differentiating human embryonic stem cells (hESCs) H1 cell line into VSMCs 
through cardiovascular progenitor cells (CVPCs) lineage [12, 15]. Since 
myocardin is the most potent driver for VSMC differentiation [16-19] and Yap has 
been showed to abolish myocardin’s function majorly by protein-protein 
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interaction [4], we hypothesized that Yap would inhibit the differentiation of 
CVPCs to VSMCs by inhibiting the function of myocardin. 
 
Materials and Methods 
Cell culture and VSMC differentiation  
Human embryonic stem cell line H1 was cultured monolayer by using 
TeSRTM-E8TM feeder free culture medium. VSMC differentiation protocol from H1 
ESCs was modified from published papers and our previous report [12, 15]. As 
VSMC differentiation from CVPC stage was our research interest, it is illustrated in 
Figure 1A. Briefly, The hESCs were digested with Versene (Life Technologies) into 
single cells and plated onto Matrigel-coated culture dishes at a density of 5×104 
cells/cm2 in CVPC induce medium (DMEM/F12, 1×B27 supplement without 
vitamin A (Life Technologies), 50 µg/mL ascorbic acid (Sigma), 25 ng/mL BMP4 
(R&D Systems), 3 µM GSK3 inhibitor CHIR99021 (Stemgent),1% pen/strep, and 
400 µM 1-thioglycerol (Sigma) ) for three days. In order to enhance cell survival, 10 
µM ROCK inhibitor Y27632 (Stemgent) was added to the medium and incubated 
overnight after cell digestion. Medium was replenished daily. For VSMCs terminal 
differentiation, CVPCs were digested into single cells by Accutase (Stemcell 
technologies) and plated on Matrigel-coated dishes at density of 2×104cells/cm2 
with VSMCs differentiation medium (DMEM/F12, 1×B27 supplement without 
vitamin A, 2 ng/mL TGF-β1 (PeproTech) ) for seven days, and Y27632 (10µM) was 
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added to the medium overnight after seeding individualized CVPCs. Primary 
human aortic VSMCs and fibroblasts were isolated by following previous report [4, 
20] and cultured in 5% fetal bovine serum (Sigma). Primary VSMCs were treated 
with identical VSMC differentiation medium for 2 days before being compared to 
CVPC-VSMCs. 
 
RNA extraction, reverse transcription and real-time quantitative polymerase 
– chain reaction 
Total RNA from cultured cells was extracted with the RNeasy Plus Micro and Mini 
kit (Qiagen), and cDNA was synthesized with the Superscript IV first-strand 
synthesis system (Invitrogen). Quantitative realtime PCR amplification was carried 
out using custom primers with iTaq SYBR supermix (Bio-Rad) as described in our 
previous reports [15].The housekeeping gene GAPDH was served as internal 
control. 
 
Western blot analysis, immunofluorescence staining and flow cytometry  
Western blot analysis was carried out as we described previously [4]. Whole cell 
lysate samples were prepared using the RIPA buffer (Thermo Fisher Scientific) 
supplemented with a protease inhibitor mixture (Roche Applied Science). 
Antibodies against GAPDH (1:1000, Santa Cruz), smooth muscle α-actin (SM 
α-actin) (1:1000, sigma), Smooth muscle Myosin heavy chain 11(SMMHC) (1:500, 
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Abcam), SM22α (1:1000; Abcam), calponin1 (1:1000, Sigma), YAP (1:1000, Cell 
signal technology) and NKX2.5 (1:200, Santa Cruz) were used to examine 
individual protein expression. Immuno-activity and band density were visualized 
by the Odyssey system (LI-COR Biosciences) according to the manufacturer’s 
instructions. 
Immunofluorescence staining was performed according to a method described 
previously [15]. The following primary antibodies against SM α-actin (1:250, sigma), 
Smooth muscle Myosin heavy chain 11(SMMHC) (1:200, Abcam), SM22α (1:250; 
Abcam), calponin1 (1:250, Sigma), YAP (1:250 Cell signal technology) were used. 
DAPI was stained with ProLong® Gold Antifade Mountant with DAPI (Life 
technologies). Stained cells were observed on an OLYMPUS microscope. 
Flow cytometry was carried out with previous protocol [15]. Primary antibody 
against Smooth muscle Myosin heavy chain 11(SMMHC) (1:200, Abcam) was 
used and Isotype IgG was used as the negative control. 
 
Infection with pLX304-lentivirus and shRNA lentivirus 
Overexpression of YAP was achieved by infection with lentivirus-based YAP 
expressing vector, pLX304-YAP (generous gift from Dr. William Hahn, Dana 
Farber Cancer Institute, Boston, MA [21], the control vector pLX304 is generous 
gift from Dr. David Root, Broad Institute of Harvard and Massachusetts Institute of 
Technology, Cambridge, MA [22]). Knockdown of YAP, TAZ or NKX2.5 
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experiments were carried out by infection with scrambled control or YAP shRNA 
lentivirus as described previously [4] (YAP shRNA is generous gift from Dr. 
Kunliang Guan, University of California, San Diego, CA), TAZ shRNA or NKX2.5 
shRNA lentivirus (shRNA plasmids are ordered from Sigma). Lentivirus was 
titrated with Lenti-XTM qRT-PCR titration kit (Clontech). For overexpression of YAP 
or knockdown of YAP, TAZ, and NKX2.5 in VSMC differentiation from CVPCs, 
differentiated CVPCs were infected twice with above viruses at day1 and day2 of 
VSMC differentiation (Figure 1A), and then infected cells were differentiated with 
VSMC differentiation medium for another three days before analysis. 
Overexpression of YAP in PAC1 cell line was also achieved with lentivirus 
pLX304-YAP and pLX304 as controls. 
 
Carbachol and angiotensin II contractility assays 
Differentiated VSMCs were stimulated with 100 µM Carbachol (Sigma) or 10 µM 
angiotensin II (MP Biomedicals). To test the specificity of angiotensin II induced 
contraction was through angiotensin II type 1 receptor, VSMCs were pretreated 
with inhibitor losartan (10µM, Sigma) for 1 h and then stimulated with 10 µM 
angiotensin II (MP Biomedicals). The contractions of cells were recorded with 
Nikon microscope and changes of cell surface area after 30 min were analyzed 
using ImageJ software. 
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Luciferase Activity Assay 
Rat smooth muscle cell line PAC1 cells (generous gift from Dr. Li Li, Wayne State 
University) were seeded in 24-well plates for 24 h. The cells then were transiently 
transfected by Lipofectamine 2000 (Invitrogen) with pGL3-MYOCD 
promoter-luciferase reporter (MYOCD WT) or the mutated promoter reporter 
without NKX2.5-binding element (MYOCD NKE mut) [23] (generous gift from Dr. 
Shiyou Chen, The University of Georgia). Thymidine kinase Renilla luciferase 
reporter vector was used for dual-luciferase assay. pcDNA-YAP plasmid was  
transfected for YAP overexpression in PAC-1. Forty-eight hours post-transfection, 
cells were lysed, and luciferase activity was detected with the Dual-Luciferase 
reporter assay system (Promega).The activity of thymidine kinase Renilla served 
as an internal standard. 
 
Chromatin Immunoprecipitation Assay (ChIP) 
ChIP assays were performed in both PAC1 and CVPC-derived VSMCs by using 
EZ-ChIP™ kit (EMD Millipore) according to manufacturer’s manual.  Chromatin 
complexes from YAP lentivirus infected cells were immunoprecipitated with 1 µg of 
Nkx2.5 antibody or IgG (negative control). Quantitative realtime PCR were 
performed to amplify the Myocd promoter region containing Nkx2.5-binding 
element (NKE) using the following primer set: for PAC1 SMC cell line: 
5-TTCCGCCTCCTCTCTGATTC-3 (forward) and 
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5-CCTTTTCCTCCTCCTCTGGG-3 (reverse); for CVPC-VSMCs: 
5-TCAGGTGATTCTCCCACCTC-3 (forward) and 
5-TCACACCTGTAATCCCAGCA-3 (reverse). 
 
Co-immunoprecipitation (Co-IP) 
For HEK293 cells, pcDNA-YAP-Myc (Addgene) and pcDNA-Nkx2.5 (generous gift 
from Dr. Shiyou Chen, The University of Georgia) were co-transfected into 
HEK293 cells, and cells were harvested 48 h post-transfection. For the process of 
CVPC-VSMCs differentiation, seeded CVPCs were infected with pLX304-YAP or 
pLX304-Vector virus at day1 and day2, and cells were harvested 3 days later. The 
Co-IP assay was performed as described in a previous report [24]. Briefly, cells 
were lysed in lysis buffer (50 mM Tris-HCl, pH 7.8, 137 mM NaCl, 1 mM EDTA, 
0.1% Triton X-100 with a protease inhibitor mixture). After centrifugation at 12,000 
rpm for 10 min at 4°C, the supernatants were collected and pre-cleared with 
protein A/G plus-agarose for 1 h at 4°C. Anti-Myc-Tag (Cell signal technology) or 
anti-YAP (Cell signaling technology) antibodies were added into pre-cleared 
supernatants and incubated overnight at 4°C. Normal IgG was used for a negative 
control. The protein complex was pulled down by incubation of A/G plus-agarose 
for 1 h at 4°C and washed three times with wash buffer (0.2mM EDTA, 100mM KCl, 
2mM Mgcl2, 0.1% Tween-20 and 10% glycerol). The immunoprecipitants were 
analyzed by Western Blotting. Immuno-activity and band density were visualized 
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by the Odyssey system (LI-COR Biosciences) according to the manufacturer’s 
instructions. 
 
Results 
Characterization of VSMCs differentiated from ESCs derived CVPCs: highly 
efficient and comparable with primary human VSMCs 
We previously established a method involving highly specific induction of CVPCs 
from human embryonic stem cells [12, 15]. In this study, we were able to further 
differentiate VSMCs through induced CVPCs by treatment with TGF-β only. The 
differentiation of VSMCs using TGF-β only was as good as that using TGF-β and 
PDGF-BB (Figure 1A, Supplement figureS1A). Flow cytometry analysis showed 
approximately 90% of differentiated VSMCs were positive by staining with the 
anti-human smooth muscle heavy chain 11 (SMMHC) antibody, which is the most 
specific differentiation marker for smooth muscle maturation (Figure 1B). The 
efficiency was consistent to the differentiation efficiency by using other SMC 
markers as we previously reported [15]. Furthermore, CVPC-VSMCs and the 
primary VSMCs shared a comparable mRNA expression level of VSMC 
contractile markers including ACTA2, TAGLN and MYH11, and all the contractile 
markers were higher than primary aortic fibroblast (Figure 1C). Primary VSMCs 
and CVPC-VSMCs showed similar and typical VSMC cell morphology and 
contractile fiber structure by immunofluorescent staining. Similar expression 
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levels of contractile proteins including smooth muscle α-actin (SM α-actin), 
calponin, SM22α, and smooth muscle heavy chain 11 (SMMHC) were detected 
between human primary VSMCs and CVPC-VSMCs by immunofluorescent 
staining (Figure 1D). To exclude the possibility of differentiation of CVPCs to 
cardiomyocytes and endothelial cells during the VSMC differentiation, we 
examined expression of MYH6, MYH7, CD31 and CD34 (Supplemental figureS1B 
and S1C). We found MYH7 was undetectable (data not shown) and other markers 
of cardiomyocytes and endothelial cells decreased during CVPC-VSMC 
differentiation. 
 
Expression of YAP decreased during VSMCs differentiation from CVPCs 
To determine role of YAP in VSMC differentiation, mRNAs transcription patterns 
of VSMCs markers and Hippo signaling were profiled during the VSMC 
differentiation from CVPCs. As shown in Figure 2A, myocardin, VSMC contractile 
markers, and SMTNB (the specific marker distinguish vascular SMCs and visceral 
SMCs) increased gradually from day 0 (CVPCs) to day 7 (mature VSMCs), while 
expression of YAP, TAZ, and TEAD4 decreased (Figure 2B, Supplemental 
figureS2). Moreover, expression of upstream kinase LATS2 and NF2 increased 
with no change in TEAD1/2/3 (Supplemental figureS2). These findings suggest 
that YAP’s function was decreased during CVPC-VSMC differentiation. These 
findings were validated by Western blot (Figure 2C) and immunofluorescent 
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analysis (Figure 2D). Taken together, we found a negative correlation between 
expression of YAP and myocardin/VSMC markers in CVPC-VSMC differentiation, 
indicating YAP was a negative regulator for VSMC differentiation from CVPCs. 
 
Overexpression of YAP decreased expression of VSMCs markers and its 
contractile function, and knockdown of YAP/TAZ increased expression of 
VSMC markers 
To further confirm YAP as a negative regulator for VSMC differentiation from 
CVPCs, the effect of YAP overexpression during VSMC differentiation from 
CVPCs was examined. As expected, overexpression of YAP significantly 
decreased mRNA and protein levels of multiple VSMC differentiation markers, 
including ACTA2, CNN, TAGLN, MYH11 and SMTNB (Figure 3A, 3B). With 
treatment of carbachol and angiotensin II, a significant decrease in contractile 
function was found in the YAP overexpressed VSMCs by quantifying the 
reduction of cell surface area (Figure 3C, 3D) (Supplemental VideoS1 and S2; S3 
and S4). Pretreating VSMCs with losartan abolished angiotensin II induced 
contraction in both YAP-overexpression and control groups, confirming a specific 
response of VSMCs to angiotensin II (Figure 3D).     
Based on the results that gain-of-function of YAP attenuated CVPCs-derived 
VSCMs differentiation, we further determined if loss-of-function of YAP would 
abolish its inhibitory effects on VSMCs differentiation from CVPCs. Given that 
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YAP and TAZ behaved complementarily and overlapping [3], knockdown of YAP 
and TAZ together was carried out with shRNA lentivirus. Compared to the 
scrambl  control group, expression of YAP and TAZ were significantly inhibited in 
shYAP and shTAZ VSMCs (Figure 4A, 4B). For VSMC markers, knockdown of 
YAP and TAZ resulted in a significant increase in expression of VSMC contractile 
markers by both RT-qPCR and Western blot (Figure 4A, 4B). Western blot was 
repeated three times and relative expression level compared to GAPDH of each 
protein was quantified (Figure 4C). 
 
YAP inhibited myocardin transcription by preventing NKX2.5 binding to 
myocardin promoter  
To further examine how YAP regulates the differentiation of VSMCs, we analyzed 
the expression of myocardin, the master regulator of VSMC differentiation. We 
found that expression of myocardin in differentiated VSMCs was down-regulated 
in YAP overexpressed group (Figure 5A) and upregulated in YAP and TAZ 
knockdown group (Figure 5B) compared to the control groups. To identify the 
potential cis-elements located in myocardin promoter that was involved in 
YAP-mediated inhibition, we compared YAP effects on both luciferase activities of 
wild type myocardin promoter and its mutant (illustrated in Figure 5C) in PAC1 rat 
SMC cell line. First, we examined the activities of luciferase reporters driven by 
the wild type 1.9kb 5’-proximal upstream DNA fragments in the myocardin gene. 
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By co-transfecting the wild type myocardin promoter luciferase plasmid and 
pcDNA-YAP construct, we found that YAP inhibited luciferase activity of the 
myocardin promoter in a dose-dependent manner compared to the pcDNA vector 
control group (Figure 5D). Transcription factor NKX2.5 was demonstrated to be 
an activator for myocardin expression both in cardiomyocytes [25] and SMCs [23, 
26] and a NKX2.5 binding element (NKE) was conserved in the myocardin 
promoter. Myocardin promoter luciferase plasmid with mutated NKX2.5 binding 
element was co-transfected with pcDNA-YAP construct. Results showed that 
YAP-mediated inhibitory effects were abolished in the NKE-mutated myocardin 
promoter luciferase reporter group (Figure 5E), indicating YAP inhibited the 
transcription of myocardin through NKX2.5. We also performed Chip-PCR on 
PAC1 SMC cells between YAP overexpression group and vector control group to 
explore the effects of YAP on NKX2.5’s binding to endogenous myocardin 
promoter. We found that YAP overexpression significantly attenuated NKX2.5’s 
binding to the endogenous myocardin promoter (Figure 5F). To explore the 
possibility that protein-protein interaction between YAP and NKX2.5 may 
contribute to YAP-mediated inhibitory effects on myocardin expression, we 
overexpressed YAP-Myc and NKX2.5 in HEK 293 cells and performed 
immunoprecipatation with an anti-Myc antibody. Immunoblotting on NKX2.5 
demonstrated that YAP-NKX2.5 protein physically interacted with each other 
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(Figure 5G), which indicated that YAP was able to bind with NKX2.5 and interfere 
NKX2.5’s transcription activation on myocardin. 
 
YAP interfered with NKX2.5 protein during CVPC-VSMC differentiation and 
attenuated VSMC differentiation in a NKX2.5 dependent manner 
Consistent with results from PAC1 cells, we found that overexpression of YAP 
inhibited NKX2.5’s binding to the myocardin promoter during CVPC-VSMC 
differentiation (Figure 6A, 6B). Moreover, knockdown of NKX2.5 decreased 
expression of myocardin and VSMC markers, which was validated by two 
shNKX2.5 constructs (Figure 6C). Based on our finding, we hypothesized that 
during CVPC-VSMC differentiation, knockdown of NKX2.5 could block the 
positive effects of YAP and TAZ knockdown on VSMC marker expression. As 
expected, further knockdown of NKX2.5 in YAP/TAZ knockdown cells showed 
(Figure 6D, Supplemental figureS3) decreased expression of myocardin and 
VSMC markers compared to the YAP and TAZ knockdown only group. These 
results indicated that YAP attenuates VSMC differentiation, at least in part, in a 
NKX2.5 dependent manner. 
 
Discussion 
In this study, we examined the function of YAP in the CVPC-VSMCs 
differentiation process and underlying mechanism. Our results showed that 
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expression of YAP decreased when CVPCs were differentiated into VSMCs 
(Figure 2). Overexpression and knockdown of YAP demonstrated that YAP 
inhibited the expression of contractile proteins and contractile function of 
CVPC-derived VSMCs (Figure 3, 4). Finally, we found that YAP decreased 
transcription of myocardin by interfering with NKX2.5’s binding to the 5’-proximal 
promoter region of myocardin gene.  
To our knowledge, this was the first study to identify that YAP inhibited the 
expression of VSMCs contractile markers through NKX2.5 during the 
differentiation process from CVPCs. Our finding is consistent with preclinical data 
showing forced expression of Yap in rodent matured SMCs down-regulated the 
expression of SMCs markers and promoted synthetic phenotypic switch [4, 5, 27]. 
However, different from our finding that knockdown of YAP and TAZ increased 
expression of myocardin and VSMC markers, significant increases of VSMC 
markers were not found in the Sm22α-Cre Yap deletion mice [8]. The possible 
reason for this difference includes increased Taz expression in Yap deletion mice 
may have compensated for the lack of Yap. As a matter of fact, this compensatory 
increase of Taz has been previously reported by Finch-Edmondson et al, when 
Yap was knocked out [28].  
Previous studies indicate that Yap1 [4] and TEAD1 proteins [29] were able to 
interfere with the function of myocardin and abolish its activation of smooth 
muscle cell contractile markers through protein-protein interaction. Similarly, our 
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results showed YAP negatively regulated function of myocardin and YAP 
attenuated function of myocardin by inhibiting transcription of myocardin in a dose 
and NKX2.5 dependent manner. As indicated herein, Nkx2.5 was an activator of 
myocardin transcription and important in the maturation of VSMCs, which is 
consistent with previous findings [23, 26]. Importantly, we found that 
protein-protein interaction between YAP and NKX2.5 mediated YAP’s inhibition 
on myocardin transcription and myocardin-driven VSMC differentiation. YAP is 
characterized with one or two WW domains (two splicing variants, YAP1 and 
YAP2, respectively) [30]. The WW domain is a protein-protein interaction module, 
which prefers to bind to ligands containing proline-rich sequences. Interestingly, a 
proline-rich sequence is conserved in human, rat, and mouse NKX2.5 proteins. It 
is quite likely that the motifs in YAP discussed above contribute to the binding to 
NKX2.5. Future studies are warranted to identify the specific protein domain 
responsible for binding between YAP and NKX2.5.    
Besides regulating VSMCs differentiation, YAP also played an important role 
in VSMC-progenitor cells development. Recent studies showed that neural 
crest-specific deletion of Yap and Taz with Wnt1-Cre or WntCre2SOR [6, 7] 
abrogated Notch signaling and caused severe neural tube vessel regression. 
Differentiation of VSMC from neural crest was interfered and resulted in aortic 
arch aneurysm and hemorrhaging. Moreover, a Tead2 binding element in the 
myocardin distal promoter has also been identified in early cardiovascular 
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development [31], suggesting that the Yap-Tead complex may be important 
during the progenitor stage of VSMC differentiation. We also found that 
expression of YAP and TAZ increased when H1 ESCs differentiated into CVPCs 
(data not shown), indicating that YAP functions variably during distinct 
differentiation stages. Taken together, YAP is very important in the development 
of the vascular system and YAP’s function may vary during different 
developmental stages. For aortic aneurysm development, besides the findings in 
rodent models [6-8], it was suggested that YAP may be a potential target for 
development of human ascending aortic aneurysms [32]. However, future studies 
with a larger human sample cohort are needed to identify the role of YAP in both 
aortic root and ascending aortic aneurysm development.  
 
Conclusion 
In conclusion, by using the in vitro ESC-CVPC-VSMCs monolayer differentiation 
model, our study demonstrated a negative regulation of YAP in the CVPC-VSMC 
differentiation process. We found YAP blocked NKX2.5’s binding to myocardin 
promoter and inhibited transcription of myocardin during this process (Figure 7). 
We identified novel modulators in VSMC differentiation and provided a potential 
target for understanding the development of aortic root aneurysm.  
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Figure1 Characterization of VSMCs differentiated from ESCs derived CVPCs: 
highly efficient and comparable with primary human VSMCs (A): Strategy of 
VSMC differentiation from CVPCs. (B): Flow cytometry analysis of SMMHC 
positive cells on CVPC and day7 VSMC. (C): Compare expression of contractile 
markers between CVPC-VSMC, primary human VSMC and primary human 
fibroblast by RT-qPCR. (D): Compare expression of contractile markers and cell 
morphology between CVPC-VSMC and primary human VSMC by 
immunofluorescence with low magnification (Left, scale bar=100 µm) and high 
magnification (Right, scale bar=20 µm). RT-qPCR was shown as average ± SEM 
(n=3). TGF-β: transforming growth factor β; CVPC: cardiovascular progenitor cell; 
VSMC: vascular smooth muscle cell; SMMHC: smooth muscle myosin heavy 
chain.  
 
Figure2 Expression of YAP decreased during VSMCs differentiated from 
CVPCs (A): Expression of VSMC markers from CVPC (D0) to VSMC (D7) by 
RT-qPCR. (B): Expression of YAP and TAZ from CVPC (D0) to VSMC (D7) 
RT-qPCR. (C): Validation of (A, B) by western blot. (D): Expression of YAP in 
CVPC and VSMC by immunofluorescence, scale bar=50 um. RT-qPCR was 
shown as average ± SEM of three independent replicates. D: day; CVPC: 
cardiovascular progenitor cell; VSMC: vascular smooth muscle cell.  
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Figure3 Overexpression of YAP attenuated differentiation of VSMCs (A)(B): 
Overexpression of YAP decreased expression of VSMC contractile markers by 
RT-qPCT (A) and western blot (B). (C): Quantification of decreased cell surface of 
VSMCs in Vector and YAP overexpressed group after Carbachol 100 uM for 30 
min. (D): Quantification of decreased cell surface of VSMCs in Vector and YAP 
overexpressed group after 30 min angiotensin II 10 uM treatment in normal 
VSMCs or losartan 10 uM pretreated VSMCs (Losartan+ANG II). Results were 
shown as average ± SEM with three independent replicates and statistic analyzed 
with unpaired t-test, *p<0.05, ***p<0.001. ANG II: angiotensin II. 
 
Figure4 Knockdown of YAP/TAZ further increased expression of VSMC 
markers (A-B): Expression of VSMC contractile markers in scramble group and 
shYAP+shTAZ group by RT-qPCR (A) and western blot (B). Bands for YAP in (B) 
were overexposed to show successful knockdown. M: molecular mass markers. 
(C): Quantification of each band’s density to GAPDH in with three independent 
western blots replicate, results were shown as average ± SEM and statistic 
analyzed with unpaired t-test. *p<0.05, **p<0.005 
 
Figure5 YAP inhibited myocardin transcription by preventing NKX2.5 
binding to myocardin promoter (A): Expression of myocardin in Vector control 
and YAP overexpressed group by RT-qPCR. (B): Expression of myocardin in 
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scramble control and shYAP+shTAZ knockdown group by RT-qPCR. (C): 
Schematic of designs of luciferase reporters. (D): Luciferase activity of 
MYOCD-promoter WT by different dose of pCDNA-YAP in PAC1 cells. (E): 
Luciferase activity of MYOCD-promoter WT and NKE mut between pCDNA 
control and pCDNA-YAP in PAC1 cells. (F): Chip-PCR assay between Vector 
control and YAP overexpressed groups in PAC1 cells. (G): Co-IP assay in HEK 
293 cells by overexpressing YAP-Myc and Nkx2.5 as indicated. Results were 
shown as average ± SEM and statistic analyzed with unpaired t-test.*p<0.05, 
**p<0.005, ***p<0.001, ns: no significance. WT: wild-type; NKE: NKX2.5 binding 
element; IP: immunoprecipitation; IB: immunoblot. M: molecular mass markers.   
 
Figure6 YAP interfered with NKX2.5 protein during CVPC-VSMC 
differentiation and attenuates VSMC differentiation in a NKX2.5 dependent 
manner. (A): Chip-PCR assays between Vector control and YAP overexpressed 
groups were confirmed in CVPC-derived VSMCs. (B): CO-IP assay on 
CVPC-derived VSMCs to detect protein-protein interaction between 
overexpressed YAP and endogenous NKX2.5. (C): Knockdown of NKX2.5 during 
CVPC-VSMC differentiation by different shRNAs: shNKX2.5-1 and shNKX2.5-2 
while sh-scramble was used as control and MYOCD and VSMC markers were 
detected by RT-qPCR. (D): Knockdown of NKX2.5 abolished effect of YAP+TAZ 
knockdown during CVPC-VSMC differentiation. Results were shown as average ± 
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SEM and statistic analyzed with unpaired t-test. *p<0.05, **p<0.01. IP: 
immunoprecipitation; IB: immunoblot. M: molecular mass markers. 
 
Figure7 Working hypothesis which elaborates role of YAP in differentiation 
of VSMC from CVPCs 
 
Supplemental figureS1 Characterization of VSMCs differentiated from 
CVPCs (A): Expression of VSMC contractile markers between TGFβ and TGF β 
pluses PDGF-BB groups. M: molecular mass marker. (B)(C): Expression of 
cardiomyocyte marker (B) and endothelial cell markers (C) in CVPC-VSMC 
differentiation. RT-qPCR was shown as average ± SEM of three independent 
replicates. TGF-β: transforming growth factor β; PDGF-BB: platelet-derived 
growth factor BB; CVPC: cardiovascular progenitor cell; SMC: smooth muscle 
cell. 
 
Supplemental figureS2 Dynamic changes of expression of other key factors 
in Hippo pathway Expression of other key factors in Hippo pathway from CVPC 
(D0) to VSMC (D7) differentiation by RT-qPCR, results are shown as average ± 
SEM of three independent replicates.  
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Supplemental figureS3 Knockdown of NKX2.5 abolished effect of YAP+TAZ 
knockdown during CVPC-VSMC differentiation (A): Successful knockdown of 
NKX2.5, YAP and TAZ by shRNAs by RT-qPCR. (B): Expression of VSMC 
markers TAGLN and CNN by RT-qPCR. Results are shown as average ± SEM 
and statistic analyzed with unpaired t-test. *p<0.05, ns: no significant. 
 
Supplemental VideoS1 Contraction of differentiated VSMCs in Vector Ctrl 
group by carbachol treatment. 
 
Supplemental VideoS2 Contraction of differentiated VSMCs in YAP 
overexpressed group by carbachol treatment. 
 
Supplemental VideoS3 Contraction of differentiated VSMCs in Vector Ctrl 
group by angiotensin II treatment. 
 
Supplemental VideoS4 Contraction of differentiated VSMCs in YAP 
overexpressed group by angiotensin II treatment. 
 
 
Supplemental TableS1 Primers used for RT-qPCR analysis.  
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Graphical Abstract Our study demonstrated a negative regulation of YAP in the 
cardiovascular progenitor cells (CVPC)-VSMC differentiation process. We found 
YAP blocked NKX2.5’s binding to myocardin promoter and inhibited transcription 
of myocardin during this process. We identified novel modulators in VSMC 
differentiation and provided a potential target for understanding the development 
of aortic root aneurysm.  
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Figure1 Characterization of VSMCs differentiated from ESCs derived CVPCs: highly efficient and comparable 
with primary human VSMCs (A): Strategy of VSMC differentiation from CVPCs. (B): Flow cytometry analysis 
of SMMHC positive cells on CVPC and day7 VSMC. (C): Compare expression of contractile markers between 
CVPC-VSMC, primary human VSMC and primary human fibroblast by RT-qPCR. (D): Compare expression of 
contractile markers and cell morphology between CVPC-VSMC and primary human VSMC by 
immunofluorescence with low magnification (Left, scale bar=100 µm) and high magnification (Right, scale 
bar=20 µm). RT-qPCR was shown as average ± SEM (n=3). TGF-β: transforming growth factor β; CVPC: 
cardiovascular progenitor cell; VSMC: vascular smooth muscle cell; SMMHC: smooth muscle myosin heavy 
chain.  
Figure 1  
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Figure2 Expression of YAP decreased during VSMCs differentiated from CVPCs (A): Expression of VSMC 
markers from CVPC (D0) to VSMC (D7) by RT-qPCR. (B): Expression of YAP and TAZ from CVPC (D0) to 
VSMC (D7) RT-qPCR. (C): Validation of (A, B) by western blot. (D): Expression of YAP in CVPC and VSMC by 
immunofluorescence, scale bar=50 um. RT-qPCR was shown as average ± SEM of three independent 
replicates. D: day; CVPC: cardiovascular progenitor cell; VSMC: vascular smooth muscle cell.  
Figure2  
113x176mm (300 x 300 DPI)  
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Figure3 Overexpression of YAP attenuated differentiation of VSMCs (A)(B): Overexpression of YAP decreased 
expression of VSMC contractile markers by RT-qPCT (A) and western blot (B). (C): Quantification of 
decreased cell surface of VSMCs in Vector and YAP overexpressed group after Carbachol 100 uM for 30 min. 
(D): Quantification of decreased cell surface of VSMCs in Vector and YAP overexpressed group after 30 min 
angiotensin II 10 uM treatment in normal VSMCs or losartan 10 uM pretreated VSMCs (Losartan+ANG II). 
Results were shown as average ± SEM with three independent replicates and statistic analyzed with 
unpaired t-test, *p<0.05, ***p<0.001. ANG II: angiotensin II.  
Figure3  
76x76mm (300 x 300 DPI)  
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Figure4 Knockdown of YAP/TAZ further increased expression of VSMC markers (A-B): Expression of VSMC 
contractile markers in scramble group and shYAP+shTAZ group by RT-qPCR (A) and western blot (B). Bands 
for YAP in (B) were overexposed to show successful knockdown. M: molecular mass markers. (C): 
Quantification of each band’s density to GAPDH in with three independent western blots replicate, results 
were shown as average ± SEM and statistic analyzed with unpaired t-test. *p<0.05, **p<0.005  
Figure4  
103x124mm (300 x 300 DPI)  
 
 
Page 35 of 43
ScholarOne Support: (434) 964-4100
Stem Cells
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Figure5 YAP inhibited myocardin transcription by preventing NKX2.5 binding to myocardin promoter (A): 
Expression of myocardin in Vector control and YAP overexpressed group by RT-qPCR. (B): Expression of 
myocardin in scramble control and shYAP+shTAZ knockdown group by RT-qPCR. (C): Schematic of designs 
of luciferase reporters. (D): Luciferase activity of MYOCD-promoter WT by different dose of pCDNA-YAP in 
PAC1 cells. (E): Luciferase activity of MYOCD-promoter WT and NKE mut between pCDNA control and 
pCDNA-YAP in PAC1 cells. (F): Chip-PCR assay between Vector control and YAP overexpressed groups in 
PAC1 cells. (G): Co-IP assay in HEK 293 cells by overexpressing YAP-Myc and Nkx2.5 as indicated. Results 
were shown as average ± SEM and statistic analyzed with unpaired t-test.*p<0.05, **p<0.005, 
***p<0.001, ns: no significance. WT: wild-type; NKE: NKX2.5 binding element; IP: immunoprecipitation; 
IB: immunoblot. M: molecular mass markers.    
Figure 5  
134x83mm (300 x 300 DPI)  
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Figure6 YAP interfered with NKX2.5 protein during CVPC-VSMC differentiation and attenuates VSMC 
differentiation in a NKX2.5 dependent manner. (A): Chip-PCR assays between Vector control and YAP 
overexpressed groups were confirmed in CVPC-derived VSMCs. (B): CO-IP assay on CVPC-derived VSMCs to 
detect protein-protein interaction between overexpressed YAP and endogenous NKX2.5. (C): Knockdown of 
NKX2.5 during CVPC-VSMC differentiation by different shRNAs: shNKX2.5-1 and shNKX2.5-2 while sh-
scramble was used as control and MYOCD and VSMC markers were detected by RT-qPCR. (D): Knockdown 
of NKX2.5 abolished effect of YAP+TAZ knockdown during CVPC-VSMC differentiation. Results were shown 
as average ± SEM and statistic analyzed with unpaired t-test. *p<0.05, **p<0.01. IP: immunoprecipitation; 
IB: immunoblot. M: molecular mass markers.  
Figure 6  
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Figure7 Working hypothesis which elaborates role of YAP in differentiation of VSMC from CVPCs  
Figure 7  
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Supplementary Table1: Primers used for qRT-PCR analysis 
 
 
Gene  Forward primer Reverse primer 
MYOCD ACGGATGCTTTTGCCTTTGAA AACCTGTCGAAGGGGTATCTG 
MYH11 AGATGGTTCTGAGGAGGAAACG AAAACTGTAGAAAGTTGCTTATTCACT 
TAGLN AGTGCAGTCCAAAATCGAGAAG CTTGCTCAGAATCACGCCAT 
ACTA2 AAAAGACAGCTACGTGGGTGA GCCATGTTCTATCGGGTACTTC 
CNN CTGTCAGCCGAGGTTAAGAAC GAGGCCGTCCATGAAGTTGTT 
SMTNB CGGCCTGCGCGTGTCTAATCC CTGTGACCTCCAGCAGCTTCCGAA 
GAPDH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 
YAP CACAGCTCAGCATCTTCGAC TATTCTGCTGCACTGGTGGA 
TAZ TCCCAGCCAAATCTCGTGATG AGCGCATTGGGCATACTCAT 
LATS2 ACCCCAAAGTTCGGACCTTAT CATTTGCCGGTTCACTTCTGC 
NF2 TTGCGAGATGAAGTGGAAAGG CAAGAAGTGAAAGGTGACTGGTT 
TEAD1 ATGGAAAGGATGAGTGACTCTGC TCCCACATGGTGGATAGATAGC 
TEAD2 CTTCGTGGAACCGCCAGAT GGAGGCCACCCTTTTTCTCA 
TEAD3 TCATCCTGTCAGACGAGGG TCTTCCGAGCTAGAACCTGTATG 
TEAD4 GAACGGGGACCCTCCAATG GCGAGCATACTCTGTCTCAAC 
NKX2.5 CTTGAGCCAGCCTGACTTTC AGGCAGAGAGACGCTTGGTA 
MYH6 CCGATAGTGCCTTTGACGTG CGACTTGTCAGCATCTTCGG 
MYH7 GACGGAGGAGGACAGGAAAA TCCTCATTCAAGCCCTTCGT 
CD31 AACAGTGTTGACATGAAGAGCC TGTAAAACAGCACGTCATCCTT 
CD34 CTACAACACCTAGTACCCTTGGA GGTGAACACTGTGCTGATTACA 
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